Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on the importance of shared decision-making in deciding which biologic would best alleviate disease burden in patients with moderate to severe atopic dermatitis.
Managing moderate to severe atopic dermatitis (AD) with biologic therapy requires shared decision-making between the dermatologist and patient to ensure that the pros and cons of each therapy are known and the right drug is given, said Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento
Transcript
Can you discuss factors to consider in recommending biologic treatment for a patient with AD, whether as monotherapy or in combination with other medications?
When I think about biologics, I'm thinking about the severity of the patient. We were trying simpler things for maybe more localized disease or mild disease, but we need to sort of up our game in terms of treatment and management strategies as disease worsens. And so dupilumab was really a game changer for the treatment of AD, because it was so effective in so many patients, and the tolerability was actually very, very good.
So, I really rarely see lack of effectiveness or issues with tolerability with dupilumab, for example. So, it's been a big success for a lot of patients and we've seen other biologics that are coming out, specifically those that just block IL-13, for example, rather than IL-4 and IL-13. That also shows promise, but, as mentioned, these therapies don't always work for every patient. Some patients aren't responders, or it’s not covered by insurance, or they're afraid of injections. So, we also have to think about other strategies. Sometimes we have to use some of the oral medications or phototherapy; methotrexate or cyclosporine, for example, are sometimes required.
So, when we start thinking about these therapies, we want to have that shared decision-making conversation with patients and talk about the pros and cons. And most of the time, I'd say with biologics, we will sort of stick with monotherapy because it works for most patients. But occasionally, we need to add on other therapies like topical steroids, as I mentioned, methotrexate, which can be used safely with dupilumab, for example.
We're starting to see new therapies populate this space. Janus kinase (JAK) inhibitors are a class that'll be very exciting for this area, but it will also have its pros and cons. So, again, I think it comes back to having that shared decision-making conversation with our patients, so that they really understand what the ups and downs of the therapies are, but more importantly, we want to make sure that we ultimately find that therapy that alleviates the burden of this disease on our patients.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen